Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2003

01-08-2003

The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

Authors: Lisa Ann Kraus, Shanti K. Samuel, Steven M. Schmid, Donald J. Dykes, William R. Waud, Marie Christine Bissery

Published in: Investigational New Drugs | Issue 3/2003

Login to get access
Metadata
Title
The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation
Authors
Lisa Ann Kraus
Shanti K. Samuel
Steven M. Schmid
Donald J. Dykes
William R. Waud
Marie Christine Bissery
Publication date
01-08-2003
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2003
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1025436307913

Other articles of this Issue 3/2003

Investigational New Drugs 3/2003 Go to the issue

OriginalPaper

Positron emission tomography (PET): Expanding the horizons of oncology drug development

OriginalPaper

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer

OriginalPaper

Immunomodulatory effects of docetaxel on human lymphocytes

OriginalPaper

A phase II trial of pemetrexed in patients with metastatic renal cancer

OriginalPaper

The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum

OriginalPaper

Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits